Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
Bos, M. K., Lam, S. W., Motta, G., Helmijr, J. C. A., Beaufort, C. M., de Jonge, E., Martens, J. W. M., Boven, E., Jansen, M. P. H. M., Jager, A., Sleijfer, S.
Published in Breast cancer research and treatment (01.07.2023)
Published in Breast cancer research and treatment (01.07.2023)
Get full text
Journal Article